175 related articles for article (PubMed ID: 30469509)
1. Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
Yamasaki K; Mukai S; Nagai T; Nakahara K; Fujii M; Terada N; Ohno A; Sato Y; Toda Y; Kataoka H; Kamoto T
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469509
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
[TBL] [Abstract][Full Text] [Related]
3. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
4. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Zoratti GL; Tanabe LM; Hyland TE; Duhaime MJ; Colombo É; Leduc R; Marsault E; Johnson MD; Lin CY; Boerner J; Lang JE; List K
Oncotarget; 2016 Sep; 7(36):58162-58173. PubMed ID: 27528224
[TBL] [Abstract][Full Text] [Related]
5. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY; Dolled-Filhart M; Ocal IT; Singh B; Lin CY; Dickson RB; Rimm DL; Camp RL
Cancer Res; 2003 Mar; 63(5):1101-5. PubMed ID: 12615728
[TBL] [Abstract][Full Text] [Related]
6. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Uhland K; Siphos B; Arkona C; Schuster M; Petri B; Steinmetzer P; Mueller F; Schweinitz A; Steinmetzer T; Van De Locht A
Int J Oncol; 2009 Aug; 35(2):347-57. PubMed ID: 19578749
[TBL] [Abstract][Full Text] [Related]
7. Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis.
Nakahara K; Yamasaki K; Nagai T; Fujii M; Akioka T; Takamori H; Terada N; Mukai S; Sato Y; Kamoto T
Res Rep Urol; 2019; 11():97-104. PubMed ID: 31114765
[No Abstract] [Full Text] [Related]
8. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
9. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
10. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation.
Yamasaki K; Mukai S; Sugie S; Nagai T; Nakahara K; Kamibeppu T; Sakamoto H; Shibasaki N; Terada N; Toda Y; Kataoka H; Kamoto T
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29890660
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of hepatocyte growth factor activation in cancer tissues.
Kawaguchi M; Kataoka H
Cancers (Basel); 2014 Sep; 6(4):1890-904. PubMed ID: 25268161
[TBL] [Abstract][Full Text] [Related]
14. Matriptase expression and zymogen activation in human pilosebaceous unit.
Wu BY; Lee SP; Hsiao HC; Chiu H; Chen CY; Yeo YH; Lee HS; Chen YW; Kaul M; Kataoka H; Johnson MD; Wang JK; Lin CY
J Histochem Cytochem; 2014 Jan; 62(1):50-9. PubMed ID: 24004857
[TBL] [Abstract][Full Text] [Related]
15. Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.
Mitchell AC; Kannan D; Hunter SA; Parra Sperberg RA; Chang CH; Cochran JR
J Biol Chem; 2018 Apr; 293(14):4969-4980. PubMed ID: 29386351
[TBL] [Abstract][Full Text] [Related]
16. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
[TBL] [Abstract][Full Text] [Related]
17. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
Ye F; Chen S; Liu X; Ye X; Wang K; Zeng Z; Su Y; Zhang XK; Zhou H
J Cell Mol Med; 2019 Jan; 23(1):155-166. PubMed ID: 30370662
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
20. Possible role of combined therapy targeting MET and pro-HGF activation for renal cell carcinoma: analysis by human HGF-producing SCID mice.
Fujii M; Akioka T; Kimura S; Nagai T; Kiwaki T; Fukushima T; Mukai S; Kamoto T
Hum Cell; 2023 Mar; 36(2):775-785. PubMed ID: 36708441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
